New drug TORL-3-600 tested in patients with advanced cancer

NCT ID NCT05948826

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times

Summary

This early-stage study tests a new drug called TORL-3-600 in 70 adults with advanced solid tumors or colorectal cancer. The main goals are to find a safe dose and check for side effects. Researchers will also see if the drug can shrink tumors or slow cancer growth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Fort Wayne Medical Oncology and Hematology Inc.

    Fort Wayne, Indiana, 46845, United States

  • Mary Crowley Cancer Research

    Dallas, Texas, 75230, United States

  • McGill University Health Centre

    Montreal, Quebec, H4A 3J1, Canada

  • Providence Medical Foundation

    Fullerton, California, 92835, United States

  • Sarah Cannon Research Institute

    Denver, Colorado, 80218, United States

  • Sarah Cannon Research Institute-Tennessee

    Nashville, Tennessee, 37203, United States

  • UCLA - JCCC Clinical Research Unit

    Los Angeles, California, 90095, United States

  • University Health Network, Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • Washington University School of Medicine-Siteman Cancer Center

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.